Compare EXAS & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | ENSG |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.5B |
| IPO Year | N/A | 2007 |
| Metric | EXAS | ENSG |
|---|---|---|
| Price | $101.54 | $175.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | $77.94 | ★ $196.40 |
| AVG Volume (30 Days) | ★ 10.8M | 319.3K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 0.14% |
| EPS Growth | N/A | ★ 35.03 |
| EPS | N/A | ★ 5.59 |
| Revenue | $3,082,033,000.00 | ★ $4,829,467,000.00 |
| Revenue This Year | $19.40 | $21.00 |
| Revenue Next Year | $13.51 | $12.30 |
| P/E Ratio | ★ N/A | $31.10 |
| Revenue Growth | 14.47 | ★ 17.55 |
| 52 Week Low | $38.81 | $118.73 |
| 52 Week High | $101.95 | $194.00 |
| Indicator | EXAS | ENSG |
|---|---|---|
| Relative Strength Index (RSI) | 89.64 | 43.79 |
| Support Level | $100.95 | $170.49 |
| Resistance Level | $101.95 | $179.73 |
| Average True Range (ATR) | 0.34 | 4.24 |
| MACD | -0.87 | -0.97 |
| Stochastic Oscillator | 59.71 | 27.25 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.